| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Transcription factor MafA; Pancreatic beta-cell-specific transcriptional activator; RIPE3b1 factor; V-maf musculoaponeurotic fibrosarcoma oncogene homolog A; MAFA |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | E.coli-derived mouse Calmegin/Clgn recombinant protein (Position: N18-D611). |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Overview
Anti-Calmegin/Clgn Antibody Picoband® is an antibody for Clgn detection raised in Rabbit (Polyclonal, Rabbit IgG), with reported reactivity: Mouse,Rat. Commonly used in WB, IHC, Flow Cytometry, ELISA workflows.
Key elements and design rationale
- Target: Clgn (MAF bZIP transcription factor A); UniProt: P52194
- Antibody format: Rabbit, Polyclonal, Rabbit IgG
- Molecular weight: 95 kDa, calculated 39411 MW
- Applications: WB, IHC, Flow Cytometry, ELISA
Vendor description (summary): Boster Bio Anti-Calmegin/Clgn Antibody Picoband® catalog # A05261-2.
Biological background
Biological context: Transcription factor that activates insulin gene expression. Acts synergistically with NEUROD1/BETA2 and PDX1. Binds the insulin enhancer C1/RIPE3b element. Binds to consensus TRE-type MARE 5'-TGCTGACTCAGCA-3' DNA sequence.
Expression and localization notes: cellular localization: Nucleus., tissue context: Preferentially expressed in regulatory T-cells (Tregs)..
Common research applications
- Western blotting (WB): Compare Clgn levels across samples and conditions using appropriate loading and biological controls.
- Immunohistochemistry (IHC): Evaluate spatial distribution of Clgn in tissue sections, considering fixation and antigen retrieval effects.
- Flow cytometry: Quantify Clgn-positive populations in single-cell suspensions with appropriate gating and controls.
- ELISA: Use antibody-based detection formats to assess antigen presence or binding in plate-based assays.
Notes for experimental interpretation
- Account for isoforms, post-translational modifications, and sample-specific processing that can shift apparent molecular weight or epitope accessibility.
- Use positive/negative biological controls where possible (e.g., known-expressing cells/tissues, knockdown/knockout models) and include appropriate secondary-only/isotype controls for imaging workflows.
Additional product notes (from provided fields)
- Background: Calmegin, also known as CLGN, is a protein which in humans is encoded by the CLGN gene. This gene belongs to the calreticulin family, which includes calreticulin, calnexin, and calmegin, and encodes a calcium-binding molecular chaperone specifically expressed in pachytene stage male germ cells. It is required for the proper folding of newly synthesized membrane proteins in the endoplasmic reticulum including those critical for sperm migration from the uterus into the oviduct and sperm adhesion to and penetration of the zona pellucida. This gene plays a key role in spermatogenesis and male infertility. Alternative splice variants exist for this gene.
- Cross reactivity: No cross-reactivity with other proteins.
- Cellular localization: Nucleus.
- Tissue details: Preferentially expressed in regulatory T-cells (Tregs).
- Research category: Signal Transduction
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.